

T-Select PEPTIDE

H-2K^b OVA Peptide

SIINFEKL

Code No.	Quantity	Concentration
TS-5001-P	100 µL	10 mg/mL

For Research Use Only. Not for administration to humans, and not for diagnostic or therapeutic use.

Peptide Sequence: SIINFEKL (8 aa)

Origin: Ovalbumin (OVA), 257-264 aa

MHC Restriction: H-2K^b

Molecular Weight: 963.14 Da

Purity: ≥90%

Formulation: 10 mg/mL peptide solution in DMSO
Handle using aseptic techniques to avoid contamination.

Storage Conditions

Store at -20°C. Repeated freeze-thaw cycles should be avoided.

Background

T lymphocytes play a central role in the immune system. Major histocompatibility complex (MHC) is important for T cell recognition of surface antigen. In humans, MHC is also called human leukocyte antigen (HLA). MHCs present epitope peptides derived from both self and non-self protein, and these MHC/peptide complexes are recognized by T cells via their T-cell receptors (TCRs). In general, CD8⁺ cytotoxic T cells (CTLs) recognize the MHC class I/peptide complex and CD4⁺ helper T cells recognize MHC class II/peptide complex. Epitope peptides binding to class I molecules typically consist of approximately 8 to 10 consecutive amino acid residues. Meanwhile, epitope peptides binding to class II molecules are not constrained in size and can vary from 11 to 30 amino acids long.

T-Select PEPTIDE is a ready-to-use epitope peptide in liquid form and this peptide is used to produce MHC Tetramer reagent. Epitope peptides enable to stimulate CTLs in an antigen-specific manner, and also to induce T-helper immunity. Therefore, T-Select PEPTIDE series are available for T cell stimulation and expansion to examine T cell functions such as cytokine production, expression of cell surface marker, cytotoxic activity, etc.

Please refer to the data sheet of MHC Tetramer reagent which comprises this epitope peptide and H-2K^b (MBL, PN TS-5001-1C) for more details.

H-2K^b OVA Tetramers

TS-5001-1C	H-2K ^b OVA Tetramer-SIINFEKL-PE
TS-5001-2C	H-2K ^b OVA Tetramer-SIINFEKL-APC
TB-5001-4	H-2K ^b OVA Tetramer-SIINFEKL-BV421
TS-M541-1	H-2K ^b OVA E1 Tetramer-EIINFEKL-PE
TS-M541-2	H-2K ^b OVA E1 Tetramer-EIINFEKL-APC
TS-M542-1	H-2K ^b OVA G4 Tetramer-SIIGFEKL-PE
TS-M542-2	H-2K ^b OVA G4 Tetramer-SIIGFEKL-APC
TS-M543-1	H-2K ^b OVA Q4H7 Tetramer-SIIQFEHL-PE
TS-M543-2	H-2K ^b OVA Q4H7 Tetramer-SIIQFEHL-APC

Mouse Strain H-2K Haplotypes

H-2K allele	H-2K ^b	H-2K ^d	H-2K ^k
Mouse strains	C57BL/-, BXSB/Mp, 129/-	BALB/c, DBA/2, NOD	C3H/He, AKR/J

References for H-2K^b OVA Peptide

- 1) Tomala J, *et al. J Immunol* **183**: 4904-4912 (2009)
- 2) Holubova J, *et al. Infect Immun* **80**: 1181-1192 (2012)

References for This Epitope

- 1) Teramoto K, *et al. Cancer Res* **63**: 7920-7925 (2003)
- 2) Li W, *et al. Infect Immun* **72**: 7005-7011 (2004)
- 3) Yajima T, *et al. J Immunol* **174**: 3590-3597 (2005)
- 4) Yajima T, *et al. J Immunol* **176**: 507-515 (2006)
- 5) Yokouchi H, *et al. Cancer Res* **97**: 148-154 (2006)
- 6) Saito K, *et al. J Immunol* **176**: 2496-2504 (2006)
- 7) Chamoto K, *et al. Cancer Res* **66**: 1809-1817 (2006)
- 8) Wakita D, *et al. Int Immunol* **18**: 425-434 (2006)
- 9) Taneichi M, *et al. J Immunol* **177**: 2324-2330 (2006)
- 10) Zhang Y, *et al. Int Immunol* **19**: 151-161 (2007)
- 11) Li W, *et al. J Immunol* **178**: 4482-4488 (2007)
- 12) Kumar H, *et al. J Immunol* **180**: 683-687 (2008)
- 13) Sugiyama T, *et al. Int Immunol* **20**: 1-9 (2008)
- 14) Wakabayashi A, *et al. J Immunol* **180**: 4000-4010 (2008)
- 15) Miyakoda M, *et al. J Immunol* **181**: 1420-1428 (2008)
- 16) Kijima M, *et al. J Immunol* **182**: 3566-3572 (2009)
- 17) Tang C, *et al. J Leukoc Biol* **86**: 187-194 (2009)
- 18) Asano J, *et al. J Immunol* **184**: 736-745 (2010)
- 19) Takeshima T, *et al. Cancer Res* **70**: 2697-2706 (2010)
- 20) Kurachi S, *et al. J Exp Med* **208**: 1605-1620 (2011)
- 21) Yanai H, *et al. PNAS* **108**: 11542-11547 (2011)
- 22) Kuwada E, *et al. Anticancer Res* **31**: 881-891 (2011)
- 23) Shimizu K, *et al. J Immunol* **190**: 5609-5619 (2013)
- 24) Yamazaki C, *et al. J Immunol* **190**: 6071-6082 (2013)

- 25) Kimura K, *et al. Infect Immun* **81**: 3825-3834 (2013)
- 26) Tsukamoto H, *et al. Cancer Immunology* **1**: 64-76 (2013)
- 27) Kobiyama K, *et al. PNAS* **111**: 3086-3091 (2014)
- 28) Ito M, *et al. PLoS ONE* **9**: e110425 (2014)
- 29) Sasaki K, *et al. Nat Commun* **6**: 7484 (2015)
- 30) Hanson MC, *et al. Clin Invest* **125**: 2532-2546 (2015)
- 31) Rapaport AS, *et al. Immunity* **43**: 1112-1124 (2015)
- 32) Toyota H, *et al. Oncol Rep* **33**: 292-296 (2015)
- 33) Takada K, *et al. Nat Immunol* **16**: 1069–1076 (2015)
- 34) Ito D, *et al. J Immunol* **195**: 934-943 (2015)
- 35) Seregin SS, *et al. J Immunol* **195**: 1112-1120 (2015)
- 36) Pearce VQ, *et al. J Immunol* **195**: 3206-3217 (2015)
- 37) Eikawa S, *et al. PNAS* **112**: 1809-1814 (2015)
- 38) Fu C, *et al. PNAS* **112**: 2823-2828 (2015)
- 39) Kamimura D, *et al. Int Immunol* **28**: 117-126 (2016)

Related Products

Please check our web site (<https://ruo.mbl.co.jp>) for up-to-date information on products and custom MHC Tetramers.